# Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity

> **NCT00608465** · PHASE4 · TERMINATED · sponsor: **Vanderbilt University** · enrollment: 4 (actual)

## Conditions studied

- Metabolic Syndrome X

## Interventions

- **DRUG:** Eplerenone
- **DRUG:** Ramipril

## Key facts

- **NCT ID:** NCT00608465
- **Lead sponsor:** Vanderbilt University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2009-05
- **Final completion:** 2011-05
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2017-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00608465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00608465, "Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00608465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*